RxSight (NASDAQ:RXST) Issues Earnings Results, Misses Estimates By $0.07 EPS

Key Points

• RxSight reported Q1 EPS of ($0.19), missing estimates by $0.07, with revenue of $30.9M (down 18.5% YoY), a GAAP net loss of $15.9M and only 20 LDDs sold, underscoring near‑term revenue and profitability pressure.
• The company reiterated full‑year 2026 guidance of $120M–$135M revenue and 70%–72% gross margin but expects a margin step‑down as higher‑cost 2025 inventory is absorbed and plans OpEx at the high end of the prior $150M–$160M range to fund commercial expansion.
• Management said LAL utilization has stabilized for a third consecutive quarter, and ongoing international expansion plus planned product enhancements should reduce adoption friction and support modest 2026 contribution with more meaningful growth in 2027 and beyond.

RxSight (NASDAQ:RXST - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07), FiscalAI reports. The firm had revenue of $30.89 million during the quarter, compared to analysts' expectations of $29.75 million. RxSight had a negative return on equity of 14.05% and a negative net margin of 28.96%.The business's revenue was down 18.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.03) EPS.

Here are the key takeaways from RxSight's conference call:

• Management says LAL utilization has stabilized for a third consecutive quarter and their customer re‑engagement programs are showing early, measurable improvements in practices that receive targeted clinical reviews and workflow support.
• Q1 sales were $30.9 million (down 18% YoY), GAAP net loss was $15.9 million, and only 20 LDDs were sold in the quarter, highlighting near‑term revenue and profitability pressure.
• The company reiterated full‑year 2026 revenue guidance of $120M–$135M and gross margin guidance of 70%–72%, but expects a margin step‑down as higher‑cost 2025 inventory is absorbed and plans OpEx at the high end of the prior $150M–$160M range to fund commercial expansion.
• International expansion is progressing (recent approval in New Zealand and activity across Europe, Korea and Australia); management expects modest 2026 contribution with the international business becoming a more meaningful growth driver in 2027 and beyond.
• RxSight plans product enhancements (PMA supplements in process) aimed at simplifying LAL implementation, reducing required LDD treatments, and extending correction range, which management says should lower adoption friction and support longer‑term growth.

RxSight Price Performance

Shares of NASDAQ:RXST traded down $0.48 during trading on Wednesday, reaching $6.78. 1,396,729 shares of the company's stock traded hands, compared to its average volume of 621,828. RxSight has a fifty-two week low of $5.90 and a fifty-two week high of $16.74. The company has a 50-day simple moving average of $7.21 and a 200-day simple moving average of $8.96.

Institutional Investors Weigh In On RxSight

Institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its position in shares of RxSight by 6.6% during the 4th quarter. Invesco Ltd. now owns 20,114 shares of the company's stock valued at $210,000 after acquiring an additional 1,249 shares during the period. Tudor Investment Corp ET AL acquired a new stake in RxSight in the 4th quarter worth about $201,000. Brevan Howard Capital Management LP boosted its holdings in RxSight by 64.3% in the 3rd quarter. Brevan Howard Capital Management LP now owns 21,616 shares of the company's stock worth $194,000 after buying an additional 8,459 shares during the last quarter. FORA Capital LLC acquired a new stake in RxSight in the 2nd quarter worth about $167,000. Finally, WINTON GROUP Ltd acquired a new stake in RxSight in the 4th quarter worth about $161,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RXST. William Blair began coverage on RxSight in a research note on Friday, January 30th. They issued a "market perform" rating for the company. Stifel Nicolaus reduced their target price on RxSight from $10.00 to $9.00 and set a "hold" rating for the company in a research note on Monday, March 9th. Needham & Company LLC restated a "buy" rating and issued a $13.00 target price on shares of RxSight in a research note on Thursday, February 26th. Piper Sandler reduced their target price on RxSight from $11.00 to $10.00 and set a "neutral" rating for the company in a research note on Thursday, February 26th. Finally, UBS Group raised their target price on RxSight from $8.00 to $9.00 and gave the stock a "neutral" rating in a research note on Thursday, February 26th. Two investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus target price of $9.78.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company's flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.